✦ LIBER ✦

An open trial of group metacognitive therapy for obsessive-compulsive disorder

✍ Scribed by Clare S. Rees; Kate E. van Koesveld

Book ID: 116617352
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 138 KB
Volume: 39
Category: Article
ISSN: 0005-7916
DOI: 10.1016/j.jbtep.2007.11.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Behavioural group therapy for obsessive–

Behavioural group therapy for obsessive–compulsive disorder in Norway. An open community-based trial

✍ Åshild Tellefsen Håland; Patrick A. Vogel; Birgit Lie; Gunvor Launes; Are Hugo P 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 218 KB

Metacognitive therapy for obsessive–comp

Metacognitive therapy for obsessive–compulsive disorder: A case series

✍ Peter L. Fisher; Adrian Wells 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 269 KB

Stepped care for obsessive-compulsive di

Stepped care for obsessive-compulsive disorder: An open trial

✍ Christina M. Gilliam; Gretchen J. Diefenbach; Sara E. Whiting; David F. Tolin 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 206 KB

Open trial of cognitive behavior therapy

Open trial of cognitive behavior therapy for childhood obsessive–compulsive disorder

✍ John Piacentini; R.Lindsey Bergman; Courtney Jacobs; James T McCracken; Jolie Kr 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Metacognitive therapy for generalized an

Metacognitive therapy for generalized anxiety disorder: An open trial

✍ Adrian Wells; Paul King 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Amisulpiride augmentation in treatment r

Amisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial

✍ Özmen Metin; Kemal Yazici; Senel Tot; Aylin Ertekin Yazici 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 1 views

## Abstract Despite the effectiveness of clomipramine and selective serotonin reuptake inhibitors (SSRIs) in the treatment of obsessive–compulsive disorder (OCD), 40% to 60% of patients who receive an adequate treatment with these agents have significant persisting symptoms. Newer atypical antipsyc